Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

BIO-1211 (Biogen).

G T Bolger1

  • 1Bio-Méga/Boehringer Ingelheim Research Inc, 2100 rue Cunard, Lavel, Quebec H7S 2G5, Canada. gbolger@lav.boehringer-ingelheim.com

Idrugs : the Investigational Drugs Journal
|August 16, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cutaneously applied acyclovir acts systemically in the treatment of herpetic infection in the hairless mouse.

Antiviral research·1997
Same author

Muscle aspartyl protease (cathepsin D) activity: detection using a chromophoric substrate and relation to wasting in DBA/2 mice implanted with leukemic L1210 tumor cells.

Canadian journal of physiology and pharmacology·1996
Same author

Competitive binding experiments reveal differential interactions for dihydropyridine calcium channel activators and antagonists at dihydropyridine receptors on mouse brain membranes.

Canadian journal of physiology and pharmacology·1994
Same author

Regional and subcellular distribution of [125I]endothelin binding sites in rat brain.

Brain research bulletin·1992
Same author

Characterization of intestinal smooth muscle responses and binding sites for endothelin.

Canadian journal of physiology and pharmacology·1992
Same author

Cardiac responses and binding sites for endothelin in normal and cardiomyopathic hamsters.

The Journal of pharmacology and experimental therapeutics·1992
Same journal

Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.

IDrugs : the investigational drugs journal·2010
Same journal

Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.

IDrugs : the investigational drugs journal·2010
Same journal

LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.

IDrugs : the investigational drugs journal·2010
Same journal

Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.

IDrugs : the investigational drugs journal·2010
Same journal

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

IDrugs : the investigational drugs journal·2010
Same journal

Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.

IDrugs : the investigational drugs journal·2010
See all related articles

Biogen and Merck are developing VLA-4 (alpha4beta1) integrin antagonists for inflammatory conditions. These specific VLA-4 inhibitors offer targeted anti-inflammatory action, with Merck advancing a lead compound for asthma into Phase II trials.

Area of Science:

  • Immunology
  • Pharmacology

Background:

  • Biogen and Merck & Co. are collaborating on novel very late antigen-4 (VLA-4) integrin antagonists.
  • These compounds are being developed for the potential treatment of various inflammatory conditions.

Purpose of the Study:

  • To investigate the therapeutic potential of VLA-4 antagonists.
  • To evaluate the efficacy and safety of lead compounds in preclinical and clinical settings.

Main Methods:

  • Development of VLA-4 (alpha4beta1) integrin antagonists.
  • Phase II clinical trials for asthma indication (Merck).
  • Preclinical research for other indications (Biogen).

Main Results:

  • VLA-4 inhibitors demonstrate anti-inflammatory effects by blocking leukocyte adhesion.

Related Experiment Videos

  • These inhibitors exhibit specificity without compromising basophil function.
  • Merck's lead compound, BIO-1211, is in Phase II trials for asthma.

    • Conclusions:

    • VLA-4 antagonists represent a promising class of drugs for inflammatory diseases.
    • The collaborative development strategy allows for targeted indications for each company.
    • Projected market entry by 2003 and significant peak sales indicate strong commercial potential.